eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | retinopathy, diabetic |
| Symptom | C0456909|blindness |
| Sentences | 29 |
| PubMedID- 20455344 | Preventing blindness due to diabetic retinopathy. |
| PubMedID- 22846399 | Our finding is, however, in keeping with the low prevalence of diabetic retinopathy as a cause of blindness observed during the nigerian national blindness and visual impairment survey . |
| PubMedID- 23653839 | diabetic retinopathy leads to blindness in diabetic persons (68). |
| PubMedID- 20957344 | Aims/hypothesis: diabetic retinopathy, the leading cause of blindness in working-age americans, is characterised by reduced neurotrophic support and increased proinflammatory cytokines, resulting in neurotoxicity and vascular permeability. |
| PubMedID- 22291637 | diabetic retinopathy, a leading cause of blindness in the developed world, has a complex pathology that affects both neuronal and vascular elements of the retina (mizutani et al., 1996; barber et al., 1998; antonetti et al., 2006; fletcher et al., 2007). |
| PubMedID- 24696994 | No case of blindness due to diabetic retinopathy was diagnosed in patients younger than 30 years of age, while the highest prevalence was found in the 70-80 age group (34%). |
| PubMedID- 25857227 | diabetic retinopathy, a major cause of blindness, is characterized by a distinct phenotype. |
| PubMedID- 22132311 | blindness as a consequence of diabetic retinopathy from long-standing or poorly controlled diabetes causes profound adverse psychological effects to the diabetic patient. |
| PubMedID- 21731317 | A retrieval system for patients with avoidable blindness due to diabetic retinopathy who do not present for ophthalmic assessment in oman. |
| PubMedID- 24525390 | Several studies have documented an improvement in the quality of care for diabetes since this was introduced,1819 and the effort may have contributed to the improvement in glycaemic control documented since the late 1990s.1720 the decline in the absolute number and relative proportion of blindness certifications due to diabetic retinopathy/maculopathy among working age adults since the introduction of these public health measures may be an indicator of their effectiveness. |
| PubMedID- 24033926 | Background: blindness due to diabetic retinopathy (dr) is the major disability in diabetic patients. |
| PubMedID- 24563789 | Tragically, this will lead to approximately 4 million people around the world losing their sight from diabetic retinopathy, the leading cause of blindness in patients aged 20 to 74 years. |
| PubMedID- 25974230 | The major breakthrough of blindness is caused due to the diabetic retinopathy. |
| PubMedID- 23393674 | The aim of this chapter is to introduce diabetic retinopathy, a leading cause of blindness in people of the working age. |
| PubMedID- 23580849 | The application of nanotechnology in medicine is undergoing rapid progress, and the recent developments in nanomedicine-based therapeutic approaches may bring significant benefits to address the leading causes of blindness associated with cataract, glaucoma, diabetic retinopathy and retinal degeneration. |
| PubMedID- 22815643 | Both glaucoma and diabetic retinopathy are leading causes of irreversible blindness worldwide.19,20 diabetes mellitus is known to cause microvascular damage and may affect the autoregulatory action of the blood vessels in the retina and optic nerve. |
| PubMedID- 23226532 | Oxidative stress is a contributing factor to the development and progression of diabetic retinopathy, a leading cause of blindness in people at working age worldwide. |
| PubMedID- 25999748 | Diabetic macular edema (dme) is the leading cause of blindness in patients with diabetic retinopathy.1 it is characterized by vascular leakage, tissue edema, and the deposition of hard exudates in the central retina.2–4 with regard to the socioeconomic burden of the disease, dme can lead to visual impairment (vi) with consequent reduction in quality of life,5–7 and patients with dme consume significantly more healthcare resources than diabetic patients without retinal complications.8 the pan-european prevalence assessment of diabetic macular edema with visual impairment (prevail) study reported an overall prevalence (among diabetic patients) of dme of 5.4%, with a prevalence of vi due to dme of 1.9%.9 given that the prevalence of diabetes mellitus has already reached epidemic proportions worldwide, and is projected to increase further over the next 20 years,10 it is expected that vi due to dme will continue to be a significant public health problem for the foreseeable future. |
| PubMedID- 24358357 | diabetic retinopathy, a major cause of blindness in developed countries worldwide , is characterized by slow and progressive alterations in the retinal microvasculature. |
| PubMedID- 20238019 | These vmd2-cre mice are potentially useful for dissecting cellular mechanisms of age-related macular degeneration or diabetic retinopathy, two leading causes of blindness with high relevance to gene expression in the rpe or muller cells. |
| PubMedID- 22125407 | When questioned about diabetic retinopathy as a cause of blindness, only 158 (39.8%) patients knew that diabetes mellitus can be sight threatening, while 239 (60.2%) were not aware until they developed sight-threatening complications. |
| PubMedID- 22371719 | Individuals with total blindness, those diagnosed with diabetic retinopathy, those with any vision impairment that could not be corrected with lenses; and those exhibiting symptoms compatible with vestibular problems at the time of the exam, such as vertigo, dizziness or ringing in the ears, were excluded from the study. |
| PubMedID- 24288441 | In addition to controlling these modifiable risk factors, regular dilated eye examinations have been shown to reduce the incidence of blindness due to diabetic retinopathy through early detection and timely treatment . |
| PubMedID- 25907958 | diabetic retinopathy, which can lead to blindness, is an end stage effect of excess cone cell death and is also associated with decreased pi3k/akt signaling . |
| PubMedID- 26576154 | Individuals with diabetes are more likely to have comorbidities than those without diabetes; it is estimated that all individuals with diabetes in canada have some form of diabetic retinopathy, a frequent cause of legal blindness, and 40 to 50% of canadians with type 1 or type 2 diabetes will manifest painful neuropathy within 10 years of diagnosis 4. |
| PubMedID- 21311662 | Researchers in cape town are investigating blindness due to diabetic retinopathy. |
| PubMedID- 25961883 | The following demographic and comorbidity characteristics were collected: age, gender, underlying cause of esrd, diabetic duration, height, weight, body mass index (bmi) bmi = weight (kg) /height (m2), presence of comorbid diseases such as hypertension, cardiovascular disease (cvd), blindness due to diabetic retinopathy, chronic pulmonary disease and malignancy. |
| PubMedID- 25945362 | The major breakthrough of blindness is caused due to the diabetic retinopathy. |
| PubMedID- 22125366 | Education is a priority for the prevention of blindness due to diabetic retinopathy. |
Page: 1